Works matching IS 03407004 AND DT 2023 AND VI 72 AND IP 6
Results: 49
Correction to: Endosialin‑positive tumor‑derived pericytes promote tumor progression through impeding the infiltration of CD8<sup>+</sup> T cells in clear cell renal cell carcinoma.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Correction to: Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Correction: Association between pre‑treatment chest imaging and pulmonary function abnormalities and immune checkpoint inhibitor pneumonitis.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Lactate from glycolysis regulates inflammatory macrophage polarization in breast cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1917, doi. 10.1007/s00262-023-03382-x
- By:
- Publication type:
- Article
Using EGFR amplification to stratify recurrent glioblastoma treated with immune checkpoint inhibitors.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1893, doi. 10.1007/s00262-023-03381-y
- By:
- Publication type:
- Article
Radiotherapy enhances CXCR3<sup>high</sup>CD8<sup>+</sup> T cell activation through inducing IFNγ-mediated CXCL10 and ICAM-1 expression in lung cancer cells.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1865, doi. 10.1007/s00262-023-03379-6
- By:
- Publication type:
- Article
Low on-treatment levels of serum soluble CD8 (sCD8) predict better outcomes in advanced non-small cell lung cancer patients treated with atezolizumab.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1853, doi. 10.1007/s00262-023-03377-8
- By:
- Publication type:
- Article
Human γδ T cells induce CD8<sup>+</sup> T cell antitumor responses via antigen-presenting effect through HSP90-MyD88-mediated activation of JNK.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1803, doi. 10.1007/s00262-023-03375-w
- By:
- Publication type:
- Article
Association between pre-treatment chest imaging and pulmonary function abnormalities and immune checkpoint inhibitor pneumonitis.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1727, doi. 10.1007/s00262-023-03373-y
- By:
- Publication type:
- Article
Endosialin-positive tumor-derived pericytes promote tumor progression through impeding the infiltration of CD8<sup>+</sup> T cells in clear cell renal cell carcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1739, doi. 10.1007/s00262-023-03372-z
- By:
- Publication type:
- Article
Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1699, doi. 10.1007/s00262-023-03370-1
- By:
- Publication type:
- Article
Effect of metformin on outcomes of patients treated with immune checkpoint inhibitors: a retrospective cohort study.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1951, doi. 10.1007/s00262-022-03363-6
- By:
- Publication type:
- Article
Real-world experience of postoperative adjuvant chemoimmunotherapy in patients with perihilar cholangiocarcinoma at high risk of recurrence.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1753, doi. 10.1007/s00262-022-03362-7
- By:
- Publication type:
- Article
Prognostic role of the innate immune signature CD163 and "eat me" signal calreticulin in clear cell renal cell carcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1779, doi. 10.1007/s00262-023-03369-8
- By:
- Publication type:
- Article
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1381, doi. 10.1007/s00262-023-03366-x
- By:
- Publication type:
- Article
Exploring the potential of combining IL-2-activated NK cells with an anti-PDL1 monoclonal antibody to target multiple myeloma-associated macrophages.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1789, doi. 10.1007/s00262-022-03365-4
- By:
- Publication type:
- Article
LINC01004-SPI1 axis-activated SIGLEC9 in tumor-associated macrophages induces radioresistance and the formation of immunosuppressive tumor microenvironment in esophageal squamous cell carcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1835, doi. 10.1007/s00262-022-03364-5
- By:
- Publication type:
- Article
Comprehensive analysis of immune subtypes reveals the prognostic value of cytotoxicity and FAP<sup>+</sup> fibroblasts in stomach adenocarcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1763, doi. 10.1007/s00262-023-03368-9
- By:
- Publication type:
- Article
Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1903, doi. 10.1007/s00262-023-03367-w
- By:
- Publication type:
- Article
Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1661, doi. 10.1007/s00262-022-03361-8
- By:
- Publication type:
- Article
Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1709, doi. 10.1007/s00262-022-03360-9
- By:
- Publication type:
- Article
Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1881, doi. 10.1007/s00262-022-03359-2
- By:
- Publication type:
- Article
Interaction of glioma-associated microglia/macrophages and anti-PD1 immunotherapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1685, doi. 10.1007/s00262-022-03358-3
- By:
- Publication type:
- Article
NLRP3 in tumor-associated macrophages predicts a poor prognosis and promotes tumor growth in head and neck squamous cell carcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1647, doi. 10.1007/s00262-022-03357-4
- By:
- Publication type:
- Article
Tumoral CD105 promotes immunosuppression, metastasis, and angiogenesis in renal cell carcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1633, doi. 10.1007/s00262-022-03356-5
- By:
- Publication type:
- Article
A nanotherapeutic system for gastric cancer suppression by synergistic chemotherapy and immunotherapy based on iPSCs and DCs exosomes.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1673, doi. 10.1007/s00262-022-03355-6
- By:
- Publication type:
- Article
Response to neoadjuvant immune checkpoint inhibitors and chemotherapy in Chinese patients with esophageal squamous cell carcinoma: the role of tumor immune microenvironment.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1619, doi. 10.1007/s00262-022-03354-7
- By:
- Publication type:
- Article
Preventive effect of tertiary lymphoid structures on lymph node metastasis of lung adenocarcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1823, doi. 10.1007/s00262-022-03353-8
- By:
- Publication type:
- Article
The common HLA class I-restricted tumor-infiltrating T cell response in HPV16-induced cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1553, doi. 10.1007/s00262-022-03350-x
- By:
- Publication type:
- Article
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1365, doi. 10.1007/s00262-022-03349-4
- By:
- Publication type:
- Article
Porphyromonas gingivalis promotes the progression of oral squamous cell carcinoma by activating the neutrophil chemotaxis in the tumour microenvironment.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1523, doi. 10.1007/s00262-022-03348-5
- By:
- Publication type:
- Article
Prevalence of mismatch repair genes mutations and clinical activity of PD-1 therapy in Chinese prostate cancer patients.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1541, doi. 10.1007/s00262-022-03347-6
- By:
- Publication type:
- Article
BAP1 and PTEN mutations shape the immunological landscape of clear cell renal cell carcinoma and reveal the intertumoral heterogeneity of T cell suppression: a proof-of-concept study.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1603, doi. 10.1007/s00262-022-03346-7
- By:
- Publication type:
- Article
Combination of magnetic hyperthermia and immunomodulators to drive complete tumor regression of poorly immunogenic melanoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1493, doi. 10.1007/s00262-022-03345-8
- By:
- Publication type:
- Article
CD20/TNFR1 dual-targeting antibody enhances lysosome rupture-mediated cell death in B cell lymphoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1567, doi. 10.1007/s00262-022-03344-9
- By:
- Publication type:
- Article
CXCL9 influences the tumor immune microenvironment by stimulating JAK/STAT pathway in triple-negative breast cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1479, doi. 10.1007/s00262-022-03343-w
- By:
- Publication type:
- Article
First-line therapy for elderly patients with advanced renal cell carcinoma in the immuno-oncology era: a network meta-analysis.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1355, doi. 10.1007/s00262-022-03341-y
- By:
- Publication type:
- Article
Different effects of NK cells and NK-derived soluble factors on cell lines derived from primary or metastatic pancreatic cancers.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1417, doi. 10.1007/s00262-022-03340-z
- By:
- Publication type:
- Article
Refurbishment of NK cell effector functions through their receptors by depleting the activity of nTreg cells in Dalton's Lymphoma-induced tumor microenvironment: an in vitro and in vivo study.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1429, doi. 10.1007/s00262-022-03339-6
- By:
- Publication type:
- Article
Cxcr3 constrains pancreatic cancer dissemination through instructing T cell fate.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1461, doi. 10.1007/s00262-022-03338-7
- By:
- Publication type:
- Article
PD-1 expression, among other immune checkpoints, on tumor-infiltrating NK and NKT cells is associated with longer disease-free survival in treatment-naïve CRC patients.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1933, doi. 10.1007/s00262-022-03337-8
- By:
- Publication type:
- Article
Pharmacological potentiation of monocyte-derived dendritic cell cancer immunotherapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1343, doi. 10.1007/s00262-022-03333-y
- By:
- Publication type:
- Article
Evaluation of the clinical molecule anti-human-PD-L1/IL-15 KD033 in the human-PD-1/PD-L1-expressing murine model demonstrates PD-L1 targeting of IL-15 in vivo.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1941, doi. 10.1007/s00262-022-03331-0
- By:
- Publication type:
- Article
Anti-4-1BB immunotherapy enhances systemic immune effects of radiotherapy to induce B and T cell-dependent anti-tumor immune activation and improve tumor control at unirradiated sites.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1445, doi. 10.1007/s00262-022-03325-y
- By:
- Publication type:
- Article
Treatment options for unresectable hepatocellular carcinoma with hepatitis virus infection following sorafenib failure.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1395, doi. 10.1007/s00262-022-03324-z
- By:
- Publication type:
- Article
TCF-1 regulates NKG2D expression on CD8 T cells during anti-tumor responses.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1581, doi. 10.1007/s00262-022-03323-0
- By:
- Publication type:
- Article
A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1405, doi. 10.1007/s00262-022-03314-1
- By:
- Publication type:
- Article
Intratumoral tertiary lymphoid structures promote patient survival and immunotherapy response in head neck squamous cell carcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1505, doi. 10.1007/s00262-022-03310-5
- By:
- Publication type:
- Article